A Bacillus coagulans with broad-spectrum antibacterial effects and its applications
By screening and identifying Bacillus coagulans NR372, the problem of poor antibacterial effect of existing Bacillus strains in the intestine has been solved, achieving effective inhibition of a variety of pathogenic bacteria and improvement of animal health, which can be applied to feed and water purification.
Patent Information
- Application Number
- CN202211395783.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-11-09
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2042-11-09
AI Technical Summary
Existing Bacillus strains have limited function in the gut microbiota and lack broad-spectrum antibacterial ability, making it difficult to effectively inhibit the growth and infection of various pathogenic bacteria.
A strain of Bacillus coagulans NR372 was screened and identified. This strain has a significant inhibitory effect on a variety of pathogenic bacteria, can survive in gastric acid and bile salt environments, and has a strong ability to produce enzymes and acids. It can be applied to feed and water purification.
Bacillus coagulans NR372 significantly inhibits pathogenic bacteria such as Escherichia coli and Salmonella, improves animal immunity, reduces diarrhea and mortality rates, and enhances animal production performance. It can be applied in the fields of livestock and aquaculture.
Smart Images

Figure DEST_PATH_IMAGE002 
Figure HDA0003933534600000011 
Figure HDA0003933534600000012
Abstract
Description
Technical Field
[0001] This invention relates to the field of functional microbial screening technology, specifically to a Bacillus coagulans with broad-spectrum antibacterial effects and its applications. Background Technology
[0002] Microecological preparations refer to formulations made using beneficial and harmless live microorganisms or bioactive substances produced by microbial metabolism, guided by microecological theory and applied according to microecological principles, through special processes to achieve the purpose of adjusting the body's microecological balance. Currently, internationally, microecological preparations are divided into three types: probiotics, prebiotics, and synbiotics. In the 1960s, as the potential harms of long-term or improper use of antibiotics in aquaculture gradually became apparent, microecological preparations gained sufficient attention in livestock farming. Since the 1990s, with the rapid development of aquaculture and the increasing prevalence of diseases in aquatic animals, aquatic microecological preparations have gradually become a research hotspot.
[0003] Adding microecological preparations to feed can improve animal immunity and disease resistance, thereby enhancing animal production performance and farming efficiency. It also reduces environmental pollution caused by the misuse and overuse of antibiotics and various chemical veterinary drugs, bringing significant ecological benefits. In aquaculture, in addition to feed-grade microecological preparations, there are also microecological preparations for water conditioning and bottom improvement. These preparations purify water quality, improve the intestinal microbiota of aquatic products, enhance digestion and absorption, promote animal growth, increase the expression level of specific immune-related genes, and enhance the body's resistance to viral and bacterial infections. Therefore, in recent years, the application of microecological preparations in animal production has been continuously expanding.
[0004] The nutritional value of feed microecology is mainly reflected in: 1) regulating the balance of gastrointestinal microecology and correcting intestinal flora dysfunction, thereby reducing infectious and non-infectious diarrhea caused by bacteria, viruses, and protozoa, as these diarrheas are all related to intestinal flora imbalance; 2) inhibiting the proliferation of pathogenic bacteria in the intestine, including amine-producing putrefactive bacteria, thereby maintaining the optimal combination and stability of intestinal flora; 3) synthesizing enzymes such as amylase, cellulase, and protease and promoting the secretion of digestive enzymes in the host, thereby promoting feed digestion and absorption and reducing diarrhea caused by indigestion; 4) synthesizing vitamins, promoting the absorption of calcium and lactose, preventing constipation and diarrhea in piglets, thereby playing a health care role for piglets; 5) the organic acids produced by metabolism can promote gastrointestinal motility, and the microecology can also moisten feces, thereby preventing constipation in sows; 6) the microecology can induce effective mucosal and humoral immune responses, enhance the host's immunity, reduce the content of endotoxins in the blood, and reduce the occurrence of diseases.
[0005] Currently, the two main feed microecologies widely used in animal production in my country are Bacillus and Lactobacillus. In practical applications, it has been found that these two feed strains, when added as exogenous beneficial bacteria to the animal gut, have both significant advantages and disadvantages that need improvement. The greatest advantage of Bacillus is its resistance to bile salts, (gastric) acid, and alkali, especially high temperatures and pressure, allowing it to survive in pelleted feed. Furthermore, it possesses good enzyme production capacity and broad-spectrum antibacterial ability. However, because Bacillus does not produce lactic acid and cannot grow well in the anaerobic environment of the intestine, it cannot play a direct role in the intestinal microecological system, limiting its effectiveness as a feed probiotic. Bacillus subtilis and Bacillus licheniformis are currently the main strains used in the production of feed-grade Bacillus preparations. For example, Zhang Bingsheng et al. screened a Bacillus subtilis strain SD-KC-001, which exhibits strong acid, salt, and heat resistance, high growth capacity, high production of enzymes such as amylase and protease, and good antibacterial ability. Animal feeding studies revealed that adding this bacterium to feed significantly improved weight gain, reduced medication costs, and lowered mortality rates. Zhou Yi et al. screened a strain of Bacillus licheniformis DN01, which exhibited strong inhibitory effects against aquatic pathogens Aeromonas hydrophila, Pseudomonas fluorescens, and Edwardsiella tarda, and significantly promoted the growth of crucian carp, greatly increasing their survival rate after viral challenge.
[0006] Developing a multifunctional, stable, and effective feed microbial strain remains a key research focus in this field. Summary of the Invention
[0007] The purpose of this invention is to provide a novel Bacillus coagulans (Bacillus) Bacillus coagulans (and its applications.) The Bacillus coagulans described herein has broad-spectrum antibacterial ability and exhibits significant inhibitory effects on pathogenic bacteria such as Escherichia coli, Salmonella, Clostridium perfringens, Staphylococcus aureus, Moraxella dysenteriae, and Vibrio, and can be widely used in the aquaculture field.
[0008] The Bacillus coagulans provided in this invention is Bacillus coagulans NR372 ( Bacillus coagulans Strain NR372 was deposited on August 4, 2022, at the China Center for Type Culture Collection, Wuhan University, China, with accession number CCTCC NO: M 20221235.
[0009] The MALDI-TOF-MS protein fingerprint of Bacillus coagulans strain NR372 provided by this invention is as follows: Figure 2 As shown, its rRNA gene fingerprint is as follows: Figure 3 As shown.
[0010] The 16S rRNA sequence of Bacillus coagulans strain NR372 provided by this invention is SEQ ID NO: 1.
[0011] The application of Bacillus coagulans strain NR372 provided in this invention in the preparation of antibacterial agents.
[0012] The application of Bacillus coagulans strain NR372 provided by this invention in water purification.
[0013] The application of Bacillus coagulans strain NR372 provided by this invention in feed production.
[0014] The present invention also provides a feed additive comprising the above-mentioned Bacillus coagulans strain NR372.
[0015] The viable count of the aforementioned Bacillus coagulans strain NR372 in the feed additive is not less than 10. 8 CFU / g.
[0016] The Bacillus coagulans NR372 obtained by screening in this invention has a strong comprehensive antibacterial effect and has a significant inhibitory effect on pathogenic bacteria such as Escherichia coli, Salmonella, Clostridium perfringens, Staphylococcus aureus, Moraxella dysenteriae, and Vibrio. Among them, the antibacterial effect is the strongest against Salmonella dysenteriae, Vibrio erwinis, and Vibrio alginolyticus, with an inhibition zone diameter of 2.8-3.5 cm.
[0017] Bacillus coagulans NR372 has strong tolerance to gastric acid, with a survival rate of up to 50% after 4 hours; this strain is completely tolerant to artificial intestinal fluid, with a survival rate as high as 100% after 12 hours; the maximum tolerance concentration of bile salts for this strain is 1%, with a survival rate of over 90% after 4 hours.
[0018] Bacillus coagulans NR372 has a strong combined ability to produce acids and enzymes, producing at least 8 kinds of organic acids and 4 kinds of enzymes. The fermentation broth has the highest content of lactic acid and acetic acid, reaching 7309.23 ug / mL and 5501.28 ug / mL, respectively. This strain has good denitrification performance, with a removal rate of 100% for both ammonia nitrogen and nitrite nitrogen. It can also efficiently degrade zearalenone, with a degradation rate of 80.5%.
[0019] Bacillus coagulans NR372 can effectively improve the production performance of weaned piglets and significantly reduce the diarrhea rate, with a significantly better effect than antibiotics. Compared with the antibiotic-fed group 1, the diarrhea index of piglets fed with Bacillus coagulans decreased by 20%-40%, which is very significant.
[0020] Bacillus coagulans NR372 significantly reduced the mortality rate of Litopenaeus vannamei infected with Vibrio parahaemolyticus. Compared with the challenge group, the mortality rate of shrimp in the probiotic treatment group fed with Bacillus coagulans NR372 decreased by 80.1%, achieving an unexpected technical effect.
[0021] The Bacillus coagulans NR372 provided by this invention is widely used in livestock and aquaculture as a feed additive, antibacterial agent, and water conditioner, and has broad application prospects. Attached Figure Description
[0022] Figure 1 This is a colony morphology diagram of strain NR372; Figure 2 This is a protein spectrum peak diagram of strain NR372; Figure 3 This is an rRNA gene fingerprint. Detailed Implementation
[0023] The *Bacillus coagulans* NR372 strain provided by this invention meets regulatory requirements. Polyphasic taxonomic identification confirms that *Bacillus coagulans* NR372 is a newly discovered strain. The *Bacillus coagulans* NR372 provided by this invention exhibits significant antibacterial effects against a variety of common pathogenic bacteria and has important application value.
[0024] The applicant submitted Bacillus coagulans NR372 ( Bacillus coagulans NR372 is deposited at the China Center for Type Culture Collection, Wuhan University, Wuhan, China, with accession number CCTCC NO: M 20221235.
[0025] The screening method described in this invention is not limited to the embodiments. Any known method capable of achieving the screening purpose can be used. The screening descriptions in the embodiments are merely illustrative of this invention and are not intended to limit the scope of protection of this invention. Any modifications or substitutions made to the methods, steps, or conditions of this invention without departing from the spirit and substance of this invention are within the scope of this invention.
[0026] The present invention will now be described in detail with reference to specific embodiments.
[0027] Example 1: Isolation and Screening of Strains 1. Sample source: 20 portions of composted and fermented feed.
[0028] 2. Initial screening and isolation of bacterial strains Weigh 1g of sample and place it in 9 mL of sterile physiological saline. Mix at 200 rpm for 10 min to obtain a bacterial suspension. Place the bacterial suspension in an 80℃ water bath for 10 min to remove non-spore-forming bacteria. Inoculate 1% of the sample into modified LB medium and incubate at 37℃ for 20 h. Dilute and spread the culture onto modified calcium carbonate identification plates. Select single colonies with soluble calcium zones and good growth, and perform Gram staining, spore staining, and catalase tests. Select four strains that are Gram-positive, spore-forming, and catalase-positive: YB95, YB115, YB202, and YB266.
[0029] 3. Secondary screening of strains Nearly 20 pathogens that frequently cause animal diseases in the livestock, poultry, aquaculture, and pet industries were selected for antibacterial tests, including Escherichia coli, Salmonella, Clostridium perfringens, Staphylococcus aureus, Moraxella dysenteriae, and Vibrio. The antibacterial ability of the four strains YB95, YB115, YB202, and YB266 obtained from the initial screening was evaluated by the size of the inhibition zone diameter.
[0030] Procedure: Take a sterile Petri dish and pour in 18-20 mL of sterile nutrient agar medium, spreading it evenly. Place the dish on a horizontal platform to solidify, forming the bottom layer. Invert the plate to divide the area evenly and label the areas to be added. Separately, take an appropriate amount of sterile semi-solid nutrient agar medium (1% agar content) and cool it to 48-50℃. Add 1-2 mL of pathogen suspension to every 50-100 mL of medium. Add 5 mL of semi-solid nutrient agar medium to each Petri dish, spreading it evenly on the bottom layer to form the bacterial layer. After cooling on a horizontal platform, evenly place 4-6 Oxford cups at equal intervals in each Petri dish. Add 0.2 mL of the expanded bacterial suspension to each Oxford cup in each double-layer Petri dish. Incubate at 37℃ for 24 hours, and measure the diameter of each inhibition zone. The specific results are shown in Table 1.
[0031] Table 1 Antibacterial effect of strains As shown in Table 1, the YB202 strain obtained in this invention exhibits the best overall antibacterial effect, demonstrating significant inhibitory effects against pathogenic bacteria such as Escherichia coli, Salmonella, Clostridium perfringens, Staphylococcus aureus, Moraxella dysenteriae, and Vibrio. Among these, it shows the strongest inhibitory effect against Salmonella pullorum, Vibrio erwinis, and Vibrio alginolyticus, with inhibition zones reaching 2.8-3.5 cm in diameter. The applicant has named this strain NR372 and will conduct further identification and functional evaluation.
[0032] Example 2 Identification of NR372 strain 1. Colony morphology identification like Figure 1 As shown, after culturing on MRS medium for 24-48 hours, NR372 strain forms round colonies with a diameter of 2-3 mm. The colonies are white and glossy, with a moist and flat surface and neat edges. Under an oil immersion microscope, the NR372 cells are rod-shaped, arranged singly, in pairs or chains, with tertiary spores.
[0033] 2. Physiological and biochemical identification Physiological and biochemical identification of strain NR372 was performed, and the results are shown in Table 2.
[0034] Physiological and biochemical characteristics of NR372 strain compared with standard Bacillus coagulans ( Bacillus coagulans The results are basically consistent and preliminarily identified as Bacillus coagulans.
[0035] Table 2 Physiological and Biochemical Tables of Strains Biochemical characteristics NR372 Standard Bacillus coagulans Indole test - - Starch hydrolysis + + Gelatin liquefaction - - Egg yolk reaction - - Tyrosine hydrolysis - - Anaerobic growth + + NaCl 2% + + NaCl 5% + + NaCl 7% - - NaCl 10% - - Note: + indicates positive; + indicates positive. a 90-100% of strains are positive; -, negative.
[0036] 3. Identification of 16S rRNA The genome of strain NR372 was extracted using a kit. Then, using this genome as a template, its 16S rRNA was amplified using specific primers 27F and 1492R.
[0037] 27F: 5'-AGAGTTTGATCATGGCTCAG-3'; 1492R: 5'-TAGGGTTACCTTACGACTT-3'.
[0038] The PCR system consisted of: 0.7 μl 27F, 0.7 μl 1492R, 4 μl template DNA, 17.5 μl SuperMiX, and 12.1 μl water. The PCR reaction conditions were set as follows: (1) 94℃ for 5 min; (2) 94℃ pre-denaturation for 30 s; (3) 55℃ for 30 s; (4) 72℃ for 1 min; and (5) 72℃ for 10 min. The amplified PCR products were detected by 1% agarose gel electrophoresis. The results showed that the PCR product size was about 1500 bp, which met the requirements.
[0039] The PCR amplification product was sent to a sequencing company for sequencing, and the results showed that the 16S rRNA sequence of strain NR372 was SEQ ID NO: 1. BLAST comparison of this sequence in the NCBI database showed the highest similarity to *Bacillus coagulans*. Therefore, strain NR372 was preliminarily identified as *Bacillus coagulans*.
[0040] 4. Identification using MALDI-TOF-MS spectra A small amount of NR372 single colony was coated onto a target plate in the form of a thin film; 1 μL of lysis buffer from the mass spectrometry sample pretreatment kit was added, and the sample was allowed to air dry at room temperature; 1 μL of matrix solution from the mass spectrometry sample pretreatment kit was added to cover the sample, and the sample was allowed to air dry at room temperature; the sample target was then placed in a mass spectrometer for identification. The identification results showed that NR372 strain is *Bacillus coagulans*, and its protein spectrum peaks are shown below. Figure 2 As shown.
[0041] 5. Ribo-Printer Fully Automated Microbial Gene Fingerprint Identification The NR372 strain was identified using the fully automated microbial gene fingerprinting system according to its operating instructions, and its rRNA gene fingerprint was obtained, as follows: Figure 3 As shown. By comparing the fingerprint of the strain with that of a known standard strain library, it was found that the NR372 strain had a similarity of more than 90% with Bacillus coagulans. Therefore, the strain was identified as Bacillus coagulans.
[0042] In summary, the applicant used three molecular biology methods—16S rRNA identification, MALDI-TOF-MS protein proteometry, and Ribo-Printer fully automated microbial genetic fingerprinting—to identify strain NR372, and the results were consistent. Combined with the colony morphology and physiological and biochemical characteristics of strain NR372, the applicant identified strain NR372 as *Bacillus coagulans*, and named it *Bacillus coagulans* NR372. Bacillus coagulans NR372).
[0043] The applicant submitted the aforementioned Bacillus coagulans NR372 ( Bacillus coagulans NR372 is deposited at the China Center for Type Culture Collection, Wuhan University, China, with accession number CCTCC NO: M20221235.
[0044] Example 3: Safety evaluation of Bacillus coagulans NR372 1. Hemolytic: The activated Bacillus coagulans strain NR372 was inoculated onto blood agar plates and incubated at 37°C for 24 hours. After that, the presence of transparent hydrolysis zones around the colonies was observed.
[0045] The results showed that no hydrolysis zone was generated around the colony, indicating that Bacillus coagulans strain NR372 does not have hemolytic activity.
[0046] 2. Drug resistance: Antibiotic resistance in strains can pose safety risks during production and application. To prevent antibiotic resistance in Bacillus coagulans NR372, its antibiotic susceptibility was studied. The minimum inhibitory concentration (MIC) of NR372 among seven common antibiotics was determined using the CLSI antibiotic susceptibility testing gradient dilution method. Sigma standards were used as antibiotics, and its susceptibility to antibiotics was assessed according to the EFSA (2012) standards. Specific results are shown in Table 3.
[0047] Table 3. Minimum inhibitory concentration (MIC) of antibiotics Chloramphenicol clindamycin Gentamicin Streptomycin Erythromycin Vancomycin tetracycline 4(S) 0.08(S) 1(S) 2(S) 1(S) 2(S) 1(S) Note: Unit is ug / ml. According to the EFSA (2012) standard for evaluating the susceptibility of strains to antibiotics, S indicates susceptibility and R indicates resistance.
[0048] As can be seen from the results in Table 3, the Bacillus coagulans NR372 provided by this invention is sensitive to all seven common antibiotics and does not exhibit drug resistance.
[0049] Example 4: Tests on the resistance of Bacillus coagulans NR372 to artificial gastrointestinal fluid and bile salts. (1) Test of tolerance to artificial gastrointestinal fluid Logarithmic growth phase Bacillus coagulans NR372 bacterial suspension was inoculated into simulated gastric fluid (pH 2.0) and simulated colonic fluid (pH 7.6) at a volume ratio of 1:9. After static incubation at 37℃ for 4 h and 12 h respectively, MRS medium was poured for incubation. The control group was physiological saline. The viable bacterial count before and after inoculation was compared by plate counting. Each sample was repeated 3 times. (2) Bile salt tolerance test Logarithmic growth phase Bacillus coagulans NR372 bacterial suspension was inoculated into MRS liquid medium with bile salt content of 0.1%, 0.2%, 0.3%, 0.5%, and 1% at a volume ratio of 1:9. After static incubation at 37°C for 4 h, MRS medium was poured cultured. The medium without bile salt treatment was used as the control group. The number of viable bacteria before and after treatment was compared by plate counting. Each sample was repeated 3 times.
[0050] The results show that Bacillus coagulans NR372 has strong tolerance to gastric acid, with a survival rate of 50% after 4 hours; the strain is completely tolerant to artificial intestinal fluid, with a survival rate of up to 100% after 12 hours; the strain has a maximum tolerance concentration of 1% for bile salts, with a survival rate of over 90% after 4 hours.
[0051] Example 5 Enzyme production characteristics of Bacillus coagulans NR372 The activated Bacillus coagulans NR372 was inoculated into MRS liquid medium and cultured at 37℃ and 220r / min for 24h to prepare the test bacterial solution for later use.
[0052] The bacterial cultures were inoculated onto selection media containing amylase, protease, cellulase, and lipase, respectively, and incubated at 37°C for 24 hours. For cellulase selection media, after incubation, 0.2% Congo red solution was added for staining for 30 minutes, followed by washing with 1 mol / L NaCl for 10 minutes, and then the size of the enzyme-producing zone was measured. For amylase selection media, dilute iodine solution was added to discolor the starch before measuring the diameter of the enzyme-producing zone. The results are shown in Table 4.
[0053] Table 4 Evaluation of enzyme production effect of Bacillus coagulans NR372 Enzyme types protease amylase Cellulase Lipase Enzyme-producing zone diameter (mm) 28 25 25 26 As can be seen from the results in Table 4, the Bacillus coagulans NR372 provided by this invention has excellent enzyme production effect.
[0054] Example 6: Acid-producing characteristics of Bacillus coagulans NR372 6.1 pH Change The activated Bacillus coagulans NR372 was inoculated into 100 mL of MRS liquid medium and cultured at 37 °C and 200 rpm for 24 h. The pH of the fermentation broth was measured at 0 h, 4 h, 8 h, 12 h, 16 h, 18 h, and 24 h.
[0055] The results showed that the pH of the Bacillus coagulans NR372 fermentation broth decreased rapidly during the 0-12h period, and the pH dropped to 4.3 at 24h.
[0056] 6.2 Determination of Organic Acid Content The fermentation broth of Bacillus coagulans NR372, after 24 hours of fermentation, was centrifuged at 5000 rpm for 10 min. The supernatant was filtered through a 0.22 μm filter and subjected to high-performance liquid chromatography (HPLC) to analyze the content of organic acids such as lactic acid and acetic acid in the fermentation broth. An acid standard curve was determined with the standard concentration (μg / mL) as the x-axis and the peak area as the y-axis. The sample peak area was substituted into the standard curve to calculate the acid content in the sample. The results are shown in Table 5.
[0057] Table 5. Analysis of organic acid content in Bacillus coagulans NR372 fermentation broth organic acids Content (ug / mL) lactic acid 7309.23 Acetic acid 5501.28 Citric acid 1600.98 Succinic acid 1534.01 Formic acid 1001.05 propionic acid 902.98 malic acid 3093.90 oxalic acid 1234.20 As can be seen from the data in Table 5, the Bacillus coagulans NR372 provided by this invention has a strong comprehensive acid production capacity, capable of producing at least 8 kinds of organic acids. The content of lactic acid and acetic acid in its fermentation broth is the highest, reaching 7309.23 ug / mL and 5501.28 ug / mL, respectively, achieving unexpected technical results.
[0058] Example 7: Removal effect of Bacillus coagulans NR372 on ammonia nitrogen and nitrite nitrogen Bacillus coagulans NR372 was inoculated into MRS liquid medium and activated at 37°C and 200 rpm for 24 h. 1 ml of the bacterial culture was then centrifuged at 4000 rpm for 5 min. The precipitate was washed three times with 0.9% physiological saline and then inoculated into 50 ml of a compound nitrogen source medium (0.1 g glucose, 0.01 g (NH4)2SO4, 0.01 g NaNO2, 1 g K2HPO4·3H2O, 0.3 g KH2PO4, 0.25 g MgSO4·7H2O, 0.05 g FeSO4·7H2O, 0.01 g MnSO4·4H2O, 30 g NaCl, pH 8.0). The initial concentrations of ammonia nitrogen and nitrite nitrogen in the compound nitrogen source medium were both 2 mg / L, and the carbon-nitrogen ratio was 10. The blank control was left untreated. After incubation at 37℃ and 150 rpm for 48 h with shaking, the supernatant was collected by centrifugation at 4500 rpm for 5 min. The contents of ammonia nitrogen and nitrite nitrogen in the supernatant were determined according to the method described in national standard GB 17378.4-2007. The removal rates of ammonia nitrogen and nitrite nitrogen by Bacillus coagulans NR372 were calculated according to the following formulas.
[0059] Ammonia nitrogen removal rate (%) = (X1-X2) / X1×100%.
[0060] Nitrite removal rate (%) = (Y1-Y2) / Y1×100%.
[0061] X1 represents the ammonia nitrogen content in the blank control after 48 hours of culture, and X2 represents the ammonia nitrogen content in the culture medium of the experimental group after 48 hours of culture; Y1 represents the nitrite nitrogen content in the blank control after 48 hours of culture, and Y2 represents the nitrite nitrogen content in the culture medium of the experimental group after 48 hours of culture.
[0062] The results showed that the Bacillus coagulans NR372 provided by the present invention has good denitrification performance, and the removal rate of both ammonia nitrogen and nitrite nitrogen reached 100%, achieving unexpected technical results.
[0063] Example 8: Degradation effect of Bacillus coagulans NR372 on zearalenone 40 μL of Bacillus coagulans NR372 fermentation broth was inoculated into 4 mL of MRS liquid medium containing zearalenone (ZEN) (10 μg / mL). An uninoculated MRS liquid medium containing ZEN (10 μg / mL) served as a blank control. The cultures were incubated at 37℃ and 200 rpm for 48 h. Following the instructions of the zearalenone ELISA kit, the culture medium was treated, and the residual ZEN in the culture medium was detected using a microplate reader to calculate the degradation rate.
[0064] Degradation rate (%) = ×100%.
[0065] The results showed that the Bacillus coagulans NR372 provided by the present invention can efficiently degrade zearalenone, with a degradation rate of 80.5%.
[0066] Example 9: Effect of Bacillus coagulans NR372 on the prevention of diarrhea in weaned piglets 1. Experimental location: Animal facility at Qingdao Agricultural University.
[0067] 2. Experimental Design: Forty healthy commercial castrated boars, weaned at (26±1) days old and with an average weight of about 7.5 kg, were selected and divided into four treatment groups, with 10 piglets in each group. They were fed in one pen for a total of four pens.
[0068] Grouping of experimental treatment groups: Control group: Basal diet group, without any antibiotics or Bacillus coagulans added; Treatment group 1: basal diet + antibiotics (50 g / t of tylosin, 50 g / t of oxytetracycline, 75 g / t of chlortetracycline); Treatment group 2: Basal diet + Bacillus coagulans NR372 (1×10) 7 CFU / g); Treatment group 3: Basal diet + Bacillus coagulans NR372 (5×10) 7 CFU / g).
[0069] The experimental pigs were fed according to the weaned piglet management program. For the first 3 days, they were fed a basal diet with free access to feed and water. The piglets were dewormed and vaccinated. On the morning of the 4th day, they were weighed on an empty stomach to begin the experimental period, which lasted 10 days. During the experimental period, they were fed three times a day with free access to water, and the temperature in the pigpen was appropriately controlled. On the 10th day of the experiment, the body weight and feed intake of all experimental pigs were measured for analysis of growth performance indicators such as average daily weight gain, average daily feed intake, feed conversion ratio, and diarrhea index. The results are shown in Table 6.
[0070] The diarrhea index is calculated using cages as the statistical unit, and the formula is as follows: Diarrhea index (%) = number of piglets with diarrhea / (number of piglets × number of days in the experiment) × 100%.
[0071] Table 6. Effects of Bacillus coagulans NR372 on growth performance of weaned piglets index control group Processing Group 1 Processing Group 2 Processing Group 3 Initial weight (kg) 7.52 7.53 7.51 7.50 Final weight (kg) <![CDATA[9.21 b ]]> <![CDATA[9.54 a ]]> <![CDATA[9.45 a ]]> <![CDATA[9.56 a ]]> Average daily weight gain (g / d) <![CDATA[168 b ]]> <![CDATA[200 a ]]> <![CDATA[193 a ]]> <![CDATA[206 a ]]> Average daily feed intake (g / d) <![CDATA[216 ab ]]> <![CDATA[242 ab ]]> <![CDATA[240 ab ]]> <![CDATA[258 a ]]> Meat-to-fat ratio <![CDATA[1.29 a ]]> <![CDATA[1.21 b ]]> <![CDATA[1.24 ab ]]> <![CDATA[1.25 ab ]]> Diarrhea index (%) <![CDATA[18 a ]]> <![CDATA[10 b ]]> <![CDATA[8 b ]]> <![CDATA[6 b ]]> As shown in Table 6, compared with the control group, the average daily weight gain and daily feed intake of each treatment group fed antibiotics and Bacillus coagulans were significantly increased, while the feed conversion ratio and diarrhea index were significantly decreased. Compared with treatment group 1 fed antibiotics, the diarrhea index of piglets in the treatment group fed Bacillus coagulans decreased by 20%-40%, which is a very significant effect. This demonstrates that the Bacillus coagulans NR372 provided by this invention can effectively improve the production performance of weaned piglets, significantly reduce the diarrhea rate of piglets, and its effect is significantly better than that of antibiotics.
[0072] Example 10: Protective effect of Bacillus coagulans NR372 on challenged Litopenaeus vannamei. 1. Source of Litopenaeus vannamei: A breeding farm in Laixi City 2. Experimental location: Azure Biological Aquaculture Room.
[0073] 3. Experimental Design: Healthy, disease-free Litopenaeus vannamei shrimp of similar size were selected and randomly divided into 4 groups, with 3 replicates per group and 10 shrimp per replicate. A 21-day culture experiment was conducted in 60L glass aquariums. During the experiment, shrimp were fed twice daily at 8:00 AM and 4:00 PM. The average water temperature was maintained at approximately 25℃, and the salinity and pH at approximately 8.0. Continuous micro-aeration was provided to maintain dissolved oxygen above 5 mg / L. After 3 days of feeding without any abnormalities, the following groupings were used for further experimentation.
[0074] (1) Control group: fed antibiotic-free basic feed, normal feeding, and no challenge with the virus; (2) Probiotic group: fed antibiotic-free basic feed + Bacillus coagulans NR372 (3×10 7 (CFU / g), normal feeding, without challenge; (3) Challenge group: fed antibiotic-free basic feed, and injected intramuscularly with Vibrio parahaemolyticus culture solution at a concentration of 1.0 × 10⁻⁶. 6 CFU / mL, injection volume 25μL; (4) Probiotic treatment group: fed antibiotic-free basic feed + Bacillus coagulans NR372 (3×10 7 After feeding for 3 consecutive days, Vibrio parahaemolyticus culture solution was injected intramuscularly at a concentration of 1.0 × 10⁻⁶ CFU / g. 6 CFU / mL, injection volume 25μL. Feed with a basal diet containing Bacillus coagulans NR372 every 3 days, and feed with the basal diet normally at other times.
[0075] The vitality, feeding, and mortality of shrimp in each group were recorded daily, and the mortality rate was calculated after 21 days. Specific results are shown in Table 7.
[0076] Table 7. Effects of Bacillus coagulans NR372 on mortality in Litopenaeus vannamei. Grouping mortality rate control group 4.95% Probiotic group 2.35% Virus attack team 66.7% Probiotic treatment group 13.3% As shown in Table 7, compared with the control group, the mortality rate of shrimp fed with the probiotic group containing Bacillus coagulans NR372 decreased by 52.5%. Shrimp in the challenge group, after injection of Vibrio parahaemolyticus, exhibited decreased feed intake, reddened appendages, empty stomach, enlarged hepatopancreas, lethargy, or wandering along the tank wall, weak vitality, and ultimately death, with a 21-day mortality rate as high as 66.7%. In contrast, the mortality rate of shrimp in the probiotic treatment group fed with Bacillus coagulans NR372 before and after injection of Vibrio parahaemolyticus was only 13.3%, a reduction of 80.1% compared to the challenge group.
[0077] The above results show that the Bacillus coagulans NR372 provided by the present invention can effectively improve the immunity of shrimp, inhibit the growth and proliferation of pathogenic bacteria such as Vibrio parahaemolyticus, and greatly reduce the mortality rate of shrimp, achieving unexpected technical effects.
Claims
1. A type of Bacillus coagulans ( Bacillus coagulans NR372, characterized in that, The preservation number of the Bacillus coagulans is CCTCC NO: M20221235.
2. The use of Bacillus coagulans as described in claim 1 in the preparation of antibacterial agents.
3. The application of Bacillus coagulans as described in claim 1 in water purification.
4. The application of Bacillus coagulans as described in claim 1 in feed production.
5. A feed additive, characterized in that, The feed additive contains the Bacillus coagulans as described in claim 1.
6. The feed additive as described in claim 5, characterized in that, The live count of Bacillus coagulans in the feed additive is not less than 10. 8 CFU / g.
7. The use of the feed additive as described in claim 5 or 6 in feed production.
Citation Information
Patent Citations
Bacillus coagulans for feeding and application thereof
CN102250817A
Bacillus coagulans having aquatic pathogen antagonistic characteristic and application of bacillus coagulans
CN105524855A
Bacillus coagulans BC99 and screening method thereof
CN111548968A
Bacillus coagulans and application thereof
CN113549574A
Bacillus coagulans BC66 and application thereof
CN113717881A
